F. Hirano et al., ALTERNATIVE SPLICING VARIANTS OF I-KAPPA-B-BETA ESTABLISH DIFFERENTIAL NF-KAPPA-B SIGNAL RESPONSIVENESS IN HUMAN-CELLS, Molecular and cellular biology, 18(5), 1998, pp. 2596-2607
To release transcription factor NF-kappa B into the nucleus, the mamma
lian I kappa B molecules I kappa B alpha and I kappa B beta are inacti
vated by phosphorylation and proteolytic degradation. Both proteins co
ntain conserved signal-responsive phosphorylation sites and have conse
rved ankyrin repeats. To confer specific physiological functions to me
mbers of the NF-kappa B/Rel family, the different I kappa B molecules
could vary in their specific NF-kappa B/Rel factor binding activities
and could respond differently to activation signals. We have demonstra
ted that both mechanisms apply to differential regulation of NF-kappa
B function by I kappa B beta relative to I kappa B alpha. Via alternat
ive RNA processing, human I kappa B beta gives rise to different prote
in isoforms. I kappa B beta 1 and I kappa B beta 2, the major forms in
human cells, differ in their carboxy-terminal PEST sequences. I kappa
B beta 2 is the most abundant species in a number of human cell lines
tested, whereas I kappa B beta 1 is the only form detected in murine
cells. These isoforms are indistinguishable in their binding preferenc
es to cellular NF-kappa B/Rel homo-and heterodimers, which are distinc
t from those of I kappa B alpha, and both are constitutively phosphory
lated. In unstimulated B cells, however, I kappa B beta 1, but not I k
appa B beta 2, is found in the nucleus, Furthermore, the two forms dif
fer markedly in their efficiency of proteolytic degradation after stim
ulation with several inducing agents tested. While I kappa B beta 1 is
nearly as responsive as I kappa B alpha, indicative of a shared activ
ation mechanism, I kappa B beta 2 is only weakly degraded and often no
t responsive at all. Alternative splicing of the I kappa B beta pre-mR
NA may thus provide a means to selectively control the amount of I kap
pa B beta-bound NF-kappa B heteromers to be released under NF-kappa B
stimulating conditions.